Flavaspidic acid BB combined with mupirocin improves its anti-bacterial and anti-biofilm activities against Staphylococcus epidermidis

Background: The increase in drug-resistant opportunistic pathogenic bacteria, especially of antibiotic-resistant Staphylococcus epidermidis (S. epidermidis), has led to difficulties in the treatment of skin and soft tissue infections (SSTI). The major reason for bacterial resistance is the formation of bacterial biofilm. Here, we report a promising combination therapy of flavaspidic acid BB (BB) and mupirocin, which can effectively eradicate the biofilm of S. epidermidis and eliminate its drug resistance. Result: The susceptibility test showed that the combination of BB and mupirocin has good antibacterial and antibiofilm activities, and the fractional inhibitory concentration index (FICI) of BB combined with mupirocin was 0.51 +/- 0.00 similar to 0.75 +/- 0.05, showing synergistic effect. Moreover, the time-kill curve assay results indicated that the combination of drugs can effectively inhibit the planktonic S. epidermidis. After drugs treatment, the drug-combination showed significantly inhibitory effects on the metabolic activity and total biomass in each stage of biofilm formation. The synergistic effect is likely related to the adhesion between bacteria, which is confirmed by field emission scanning electron microscope. And the expression level of cap, sarA and agrA genes were detected by real-time quantitative PCR (qRT-PCR). Conclusion: Our study provides the experimental data for the use of BB for the clinical treatment of skin infections and further demonstrate the potential of BB as a novel biofilm inhibitor.

Automated summary

This study reports a promising combination therapy of flavaspidic acid BB and mupirocin, which can effectively eradicate Staphylococcus epidermidis biofilm and eliminate its drug resistance. The combination therapy shows synergistic effects in inhibiting planktonic bacteria and biofilm formation, possibly due to the adhesion between bacteria. This research provides experimental data for the clinical treatment of skin infections and demonstrates the potential of BB as a novel biofilm inhibitor.